For Immediate Release
Oak Brook, IL (March 29, 2021) – The April edition of SLAS Discovery is a special issue on advances in protein degradation curated by guest editors M. Paola Castaldi, Ph.D., and Stewart L. Fisher, Ph.D.
Targeted protein degradation has generated interest within the drug discovery arena due to the inhibition of one particular function of a protein not often delivering the successful results that comes from whole-protein depletion. The pharmacology of PROTACs present challenges, however, namely for the development of orally bioavailable drugs. In the article “Target Validation Using PROTACs: Applying the Four Pillars Framework” authors Rados?aw P. Nowak, Ph.D., and Lyn H. Jones, Ph.D., describe the application of a translational pharmacology framework (the four pillars) to expedite PROTAC development by informing pharmacokinetic–pharmacodynamic (PKPD) understanding and helping clarify structure–activity relationships. Nowak and Jones hope that the four pillars will serve as a useful guideline to those developing targeted protein degraders and help establish PROTAC molecules as target validation chemical probes.
The April issue of SLAS Discovery includes three articles of original research.
Other articles include:
Access to April’s SLAS Discovery issue is available at https://journals.sagepub.com/toc/jbxb/current. For more information about SLAS and its journals, visit www.slas.org/publications. Access a “behind the scenes” look at the latest issue with SLAS Discovery Author Insights podcast. Tune in by visiting https://www.buzzsprout.com/1099559.
SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS Discovery: Advancing the Science of Drug Discovery, 2019 Impact Factor 2.195. Editor-in-Chief Robert M. Campbell, Ph.D., Twentyeight-Seven Therapeutics, Boston, MA (USA).
SLAS Technology: Translating Life Sciences Innovation, 2019 Impact Factor 2.174. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore).
Director of Marketing Communications
Telephone: +1.630.256.7527, ext. 103